524 completed. 524 Phase 1, 78 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 524 | Completed 524 |
| Phase 2 | 78 | Completed 78 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2) - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 8 | 2025-09-29 | 2026-04-03 |
| Intraoperative Midazolam on Delirium Outcome of Elderly Patients Midazolam, Saline - Delirium, Anxiety | Phase 1 | Completed | Chinese PLA General Hospital | 612 | 2025-09-01 | 2026-09-02 |
| Project CARE-D - Online Caregiver Education for Dementia Structured Retrieval Practice, Business as usual learning, Standard Retrieval Practice - Dementia | Phase 1 | Completed | Texas Christian University | 65 | 2025-05-01 | 2026-02-04 |
| A Study of NH280105 in Healthy Adult Participants NH280105- SAD, NH280105- MAD, Placebo - Alzheimer Disease | Phase 1 | Completed | Jiangsu Nhwa Pharmaceutical Co., Ltd. | 32 | 2025-03-12 | 2026-01-15 |
| Phenserine on the Alzheimer's Treatment Horizon, Study 1 Phenserine, Donepezil (Aricept®) - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | Completed | Helse Stavanger HF | 16 | 2025-02-01 | 2026-05-04 |
| Learn About Caring for a Person Living With Dementia Structured Retrieval Practice (SRP), Standard Health Education - Dementia | Phase 1 | Completed | Texas Christian University | 73 | 2025-01-01 | 2026-02-02 |
| Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI Sublingual administration, Electroencephalography, Biochemical mesurements - Mild Cognitive Impairment, Anxiety State | Phase 1 / Phase 2 | Completed | Biomind Labs Inc. | 20 | 2024-12-15 | 2025-04-09 |
| Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 VES001 - Dementia, Frontotemporal Dementia | Phase 1 | Completed | Mads Kjolby | 6 | 2024-12-12 | 2025-08-24 |
| A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003) MK-1708, Itraconazole - Alzheimer's Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 12 | 2024-10-03 | 2024-12-18 |
| Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets LPM3770164 sustained release tablet - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 16 | 2024-07-31 | 2024-12-12 |
| Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution Exosome Secretome - Motor Disorders | Phase 1 | Completed | The Foundation for Orthopaedics and Regenerative Medicine | 70 | 2024-07-14 | 2026-10-16 |
| Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease NMRA-323511, Placebo - Alzheimer's Disease, Healthy Elderly | Phase 1 | Completed | Neumora Therapeutics, Inc. | 87 | 2024-07-09 | 2026-05-22 |
| A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants sabirnetug (ACU193), Sabirnetug + rHuPH20 - Alzheimer Disease | Phase 1 | Completed | Acumen Pharmaceuticals | 28 | 2024-06-25 | 2024-10-18 |
| Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine AV-1959R (Abeta vaccine) - Alzheimer Disease, Alzheimer Disease (AD) | Phase 1 | Completed | Nuravax, Inc. | 16 | 2024-06-12 | 2026-09-15 |
| A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants ALIA-1758, Placebo - Alzheimer Disease | Phase 1 | Completed | AbbVie | 53 | 2024-05-09 | 2025-07-17 |
| A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease SHR-1707 injection, Placebo - Alzheimer's Disease (AD) | Phase 1 | Completed | Atridia Pty Ltd. | 2 | 2024-04-17 | 2025-07-11 |
| Remimazolam for Emergence Delirium Prevention in Children Undergoing Tonsillectomy Remimazolam 20 MG Injection [Byfavo], NaCl (0,9%) - Remimazolam, Tonsillectomy | Phase 1 | Completed | University Hospital of Split | 110 | 2024-04-01 | 2026-07-15 |
| Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) MK-1167, Donepezil, Placebo - Alzheimer's Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 28 | 2024-03-28 | 2025-10-14 |
| Decreasing Emergence Delirium With Personalized Music Personalized Music, No Music - Emergence Delirium | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 394 | 2024-01-26 | 2026-07-23 |
| Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease Leucettinib-21 - Healthy Volunteers, Down Syndrome | Phase 1 | Completed | Perha Pharmaceuticals | 152 | 2024-01-18 | 2026-06-30 |
Showing 20 of 524. Sign in to see all of them.
Alzheimer Disease (384) · Cognitive Dysfunction (83) · Dementia (62) · Huntington Disease (32) · Parkinson Disease (13) · Memory Disorders (12) · Pick Disease of the Brain (11) · Central Nervous System Diseases (10) · Cognition Disorders (10) · Frontotemporal Dementia (10) · Neurodegenerative Diseases (9) · Schizophrenia (8) · Anxiety Disorders (6) · Depression (6) · HIV Infections (6)
Mental Disorders (519) · Nervous System Diseases (478) · Brain Diseases (454) · Central Nervous System Diseases (450) · Neurodegenerative Diseases (411) · Dementia (391) · Tauopathies (382) · Cognition Disorders (109) · Pathological Conditions, Signs and Symptoms (73) · Neurologic Manifestations (54) · Signs and Symptoms (53) · Basal Ganglia Diseases (48) · Movement Disorders (47) · Neurobehavioral Manifestations (39)
Donepezil (25) · florbetapir (11) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (10) · BMS 708163 (10) · SAM-531 (9) · latrepirdine (9) · Midazolam (8) · atabecestat (8) · Saline Solution (5) · ponezumab (5) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (4) · Caffeine (4) · Dexmedetomidine (4) · Iodine-123 (4) · N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide (4)
Wyeth is now a wholly owned subsidiary of Pfizer (26) · Pfizer (21) · Merck Sharp & Dohme LLC (18) · GlaxoSmithKline (15) · Eli Lilly and Company (14) · Avid Radiopharmaceuticals (12) · Bristol-Myers Squibb (11) · AstraZeneca (10) · Eisai Inc. (8) · Institute for Neurodegenerative Disorders (8) · Janssen Research & Development, LLC (8) · Mayo Clinic (7) · Cognition Therapeutics (6) · Genentech, Inc. (6) · Hoffmann-La Roche (6)
United States (312) · United Kingdom (33) · Sweden (26) · Australia (24) · Japan (22) · Netherlands (22) · Germany (20) · Canada (19) · France (17) · South Korea (15) · Belgium (13) · China (13) · Austria (7) · Finland (6) · Spain (5)
Danna Jennings, MD (8) · Danielle Armas, MD (3) · Adam Mecca, MD, PhD (2) · Anthony Caggiano, MD (2)
PMID 37996817, PMID 25789616, PMID 26925577, PMID 27955995, PMID 29063518, PMID 30134967, PMID 30355322, PMID 33788154, PMID 34521461, PMID 39390616, PMID 41220869, PMID 12770610, PMID 1538192, PMID 15577929, PMID 15852017, PMID 16375711, PMID 17951067, PMID 18204357, PMID 18580589, PMID 19320056, PMID 19420314, PMID 19812460, PMID 20679141, PMID 21644059, PMID 21723605, PMID 22172392, PMID 22252372, PMID 22381714, PMID 22409311, PMID 22431837, PMID 22666474, PMID 22677258, PMID 22717030, PMID 22986776, PMID 23076723, PMID 23152610, PMID 23289819, PMID 23300829, PMID 23817284, PMID 24077434, PMID 24131736, PMID 24195007, PMID 24260218, PMID 24716469, PMID 24878825, PMID 24970906, PMID 25022459, PMID 25223836, PMID 25404952, PMID 25426834
2016 (6), 2015 (4), 2014 (3), 2017 (3), 2009 (2), 2018 (2), 2019 (2), 2023 (2), 1RF1AG051514 (1), 1RF1AG058067-01A1 (1), 1UF1AG046148 (1), 1UH2TR000967-01 (1), 2008 (1), K01AA026005 (1), K01AG054731 (1)